Skip navigation

Signatera™
for Lung Cancer

Personalized, tumor-informed testing for molecular residual disease (MRD) to inform lung cancer care across the treatment journey.

Know More, Sooner

Test

Identify High Risk Patients

Test for presence of MRD after definitive therapy to assess prognosis1-2

93%-100%

sensitivity for predicting recurrence1-2

Know

Detect Recurrence Earlier

Detect recurrence before radiographic imaging1-2

4-5 months

mean lead time over radiographic recurrence1-2

Decide

Monitor Treatment Response

Track changes in ctDNA levels to evaluate treatment response3

100% OS*

for patients who cleared ctDNA during IO (immunotherapy)3

Get Started

Evaluate Response to ICI Treatment

ICIs (immune checkpoint inhibitors) are FDA-approved with guideline recommendations across all treatment settings in lung cancer (neoadjuvant, adjuvant, locally advanced, metastatic).4

The Signatera™ Residual Disease Test was evaluated in the INSPIRE trial, a randomized, prospective study in patients with advanced or metastatic solid malignancies receiving an anti-PD-1 treatment:3

  • An increase in ctDNA levels from baseline to week 6 strongly predicted disease progression and nonresponse to treatment.3

  • Overall survival was 100% in patients who experienced ctDNA clearance for at least one on-treatment time point.3

Inform Your Lung Cancer Treatment Approach With Signatera™

Monitoring circulating tumor DNA (ctDNA) with Signatera™ across the treatment journey can answer important clinical questions and inform treatment decisions.

alt text

Do More With Less Tissue

One tumor sample – two tests

Add the Altera™ tumor genomic profiling test when you order Signatera™ to get clinically relevant biomarkers (eg EGFR, KRAS, ALK, ROS1, MSI, TMB) and MRD monitoring with no additional sample.

Reassure Your Patients Living With Lung Cancer

After JoAnn was diagnosed with lung cancer, Signatera™ detected a rise in her ctDNA levels, alerting her oncologist to a progression that was not scannable.

Watch JoAnn’s story to learn how she and her oncologist added Signatera™ testing to their toolbelt to help closely monitor her cancer.

“I want to know. The more you know, the better off you are.” – JoAnn, living with lung cancer

Enroll Your Lung Cancer Patients in the BESPOKE IO Trial

The BESPOKE IO clinical study is a trial for patients living with NSCLC and other solid tumor types who will receive standard of care treatment with ICIs. The study will determine how serial Signatera™ testing impacts treatment decisions and early detection of disease progression when integrated as part of routine assessment of tumor response.

Lung Cancer Resources

Medicare Coverage

Signatera™ is covered by Medicare for immunotherapy treatment response monitoring across all solid tumor types and stages of cancer.

IO Monitoring Brochure

Learn how Signatera™ can assess immunotherapy response as early as 6 weeks into treatment for patients with solid tumors.3

Patient Case Study

Read how Signatera™ detected a rise in ctDNA levels during immunotherapy, informing the decision to pivot to a combination therapy approach.

Ready to try Signatera™ for your lung cancer patients?



*OS = Overall Survival

References

1Abbosh C, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451. https://doi.org/10.1038/nature22364

2Lebow ES, et al. Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non-small cell lung cancer (NSCLC) treated with definitive radiation therapy. Journal of Clinical Oncology 2022 40:16_suppl, 8540-8540. https://doi.org/10.1200/JCO.2022.40.16_suppl.8540

3Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1(9):873-881. https://doi.org/10.1038/s43018-020-0096-5

4NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 3.2022